trending Market Intelligence /marketintelligence/en/news-insights/trending/5E_zVbX1w9FputCrYP20tw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

EMA grants PRIME access to BioMarin's hemophilia A therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

EMA grants PRIME access to BioMarin's hemophilia A therapy

The European Medicines Agency granted access to the priority medicines regulatory initiative to BioMarin Pharmaceutical Inc.'s investigational gene therapy drug for severe hemophilia A, which causes increased bleeding and usually affects males.

The agency's Committee for Medicinal Products for Human Use determined the PRIME access was justified due to the therapy's preliminary clinical data in affected patients, supporting that a single IV administration results in sustained restoration of factor VIII activity, reduction of annualized bleeding rates and improved quality of life.